2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
405
Brain Neoplasms
163
Glioma
159
Gliosarcoma
131
Astrocytoma
115
Central Nervous System Neoplasms
110
Melanoma
75
Oligodendroglioma
74
Neuroblastoma
44
Neoplasms
33
Medulloblastoma
33
Neoplasm Metastasis
29
Recurrence
28
Ependymoma
26
Sarcoma
23
Sarcoma, Ewing
22
Rhabdomyosarcoma
18
Small Cell Lung Carcinoma
16
Lymphoma
16
Carcinoma, Non-Small-Cell Lung
16
Diffuse Intrinsic Pontine Glioma
15
Lung Neoplasms
14
Breast Neoplasms
14
Ovarian Neoplasms
13
Neuroendocrine Tumors
13
Choroid Plexus Neoplasms
13
Optic Nerve Glioma
11
Neuroectodermal Tumors, Primitive
11
Spinal Cord Neoplasms
10
Rhabdoid Tumor
10
Interventions
Levetiracetam
6
Cannabidiol
5
perampanel
2
Tranexamic Acid
2
Standard of Care
2
Everolimus
2
ziprasidone
1
enzalutamide
1
Zolpidem
1
Warfarin
1
Vigabatrin
1
Vecuronium Bromide
1
Vancomycin
1
Tobramycin
1
Temozolomide
1
Spironolactone
1
Solutions
1
Sodium Chloride
1
Sevelamer
1
Saline Solution
1
Rocuronium
1
Remifentanil
1
Propofol
1
Pregabalin
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Nifedipine
1
Nafcillin
1
Molindone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Seizures
×
Temozolomide
×
Clear all
NCT04450160
2020-06-29
AEO
MetVital, Inc.
Phase 2
Unknown
80 enrolled